14436 Federal Register / Vol. 60, No. 52 / Friday, March 17, 1995 / Notices

42 CFR 447.53(d) Imposition of Cost

Sharing Charges Under Medicaid

(BERC–509);

Form No.: HCFA–R53;

Use: The information collection

requirement at 42 CFR 447.53(d)

requires the States to include in their

Medicaid State plan their provisions for

imposition of cost sharing on the

medically and categorically needy;

Respondents: State or local

government;

Number of Respondents: 54;

Total Annual Responses: 54;

Total Annual Hours Requested: 2,700.

4. Type of Request: Reinstatement;

Title of Information Collection:

Medicare Current Beneficiary Survey—

Community Component Supplement

PR: ‘‘Sources Of Information About

Medicare’’;

Form No.: HCFA–P–0015A;

Use: This supplement is intended to

find out from a systematic sample of

Medicare beneficiaries, how they obtain

information about program rules and

procedures when they need it. It also

elicits their opinion of the adequacy of

the information they found, and

alternative means by which HCFA

might provide this information;

Respondents: Individuals and

households;

Number of Respondents: 12,000;

Total Annual Responses: 12,000;

Total Annual Hours Requested: 2,000.

5. Type of Request: Reinstatement;

Title of Information Collection:

Application for Hospital Insurance;

Form No.: HCFA–18;

Use: This form is used to establish

entitlement to Hospital Insurance and

Supplementary Medical Insurance for

beneficiaries covered under only title

XVIII of the Social Security Act;

Respondents: Business or other for

profit, Federal Government, State or

local government, farms, individuals

and households;

Number of Respondents: 50,000;

Total Annual Responses: 50,000;

Total Annual Hours Requested:

12,500.

Additional Information or Comments:

Call the Reports Clearance Office on

(410) 966–5536 for copies of the

clearance request packages. Written

comments and recommendations for the

proposed information collections

should be sent within 30 days of this

notice directly to the OMB Desk Officer

designated at the following address:

OMB Human Resources and Housing

Branch, Attention: Allison Eydt, New

Executive Office Building, Room 10235,

Washington, DC 20503.

Dated: March 7, 1995.

Kathleen B. Larson,

Director, Management Planning and Analysis

Staff, Office of Financial and Human

Resources, Health Care Financing

Administration.

[FR Doc. 95–6553 Filed 3–16–95; 8:45 am]

BILLING CODE 4120–03–P

Food and Drug Administration

Advisory Committees; Notice of

Meetings

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: This notice announces

forthcoming meetings of public advisory

committees of the Food and Drug

Administration (FDA). This notice also

summarizes the procedures for the

meetings and methods by which

interested persons may participate in

open public hearings before FDA’s

advisory committees.

FDA has established an Advisory

Committee Information Hotline (the

hotline) using a voice-mail telephone

system. The hotline provides the public

with access to the most current

information on FDA advisory committee

meetings. The advisory committee

hotline, which will disseminate current

information and information updates,

can be accessed by dialing 1–800–741–

8138 or 301–443–0572. Each advisory

committee is assigned a 5-digit number.

This 5-digit number will appear in each

individual notice of meeting. The

hotline will enable the public to obtain

information about a particular advisory

committee by using the committee’s 5-

digit number. Information in the hotline

is preliminary and may change before a

meeting is actually held. The hotline

will be updated when such changes are

made.

MEETINGS: The following advisory

committee meetings are announced:

Clinical Chemistry and Clinical

Toxicology Devices Panel of the

Medical Devices Advisory Committee

Date, time, and place. April 6 and 7,

1995, 9 a.m., Holiday Inn—

Gaithersburg, Whetston and Walker

Rooms, Two Montgomery Village Ave.,

Gaithersburg, MD. A limited number of

overnight accommodations have been

reserved at the Holiday Inn—

Gaithersburg. Attendees requiring

overnight accommodations may contact

the hotel at 301–948–8900 and reference

the FDA Panel meeting block.

Reservations will be confirmed at the

group rate based on availability.

Type of meeting and contact person.

Open public hearing, April 6, 1995, 9

a.m. to 10 a.m., unless public

participation does not last that long;

open committee discussion, 10 a.m. to

4 p.m.; open public hearing, April 7,

1995, 9 a.m. to 10 a.m., unless public

participation does not last that long;

open committee discussion, 10 a.m. to

4 p.m., Cornelia B. Rooks, Center for

Devices and Radiological Health (HFZ–

440), Food and Drug Administration,

2098 Gaither Rd., Rockville, MD 20850,

301–594–1243, or FDA Advisory

Committee Information Hotline, 1–800–

741–8138, (301–443–0572 in the

Washington, DC area), Clinical

Chemistry and Clinical Toxicology

Devices Panel, code 12514.

General function of the committee.

The committee reviews and evaluates

data on the safety and effectiveness of

marketed and investigational devices

and makes recommendations for their

regulation.

Agenda—Open public hearing.

Interested persons may present data,

information, or views, orally or in

writing, on issues pending before the

committee. Those desiring to make

formal presentations should notify the

contact person before March 30, 1995,

and submit a brief statement of the

general nature of the evidence or

arguments they wish to present, the

names and addresses of proposed

participants, and an indication of the

approximate time required to make their

comments.

Open committee discussion. On April

6, 1995, the committee will discuss a

premarket approval application for a

fetal fibronectin enzyme immunoassay

which is to be used in symptomatic

women as an aid in the prediction of

impending preterm delivery. On April

7, 1995, the committee will discuss a

group of 510(k) applications pertaining

to sweat patch collection of drugs of

abuse and their measurement. The

collection devices are intended for use

by professionals in drug treatment

programs.

Pulmonary-Allergy Drugs Advisory

Committee

Date, time, and place. April 10, 1995,

8 a.m., Holiday Inn, Plaza Ballroom,

8777 Georgia Ave., Silver Spring, MD.

Type of meeting and contact person.

Open public hearing, 8 a.m. to 9 a.m.,

unless public participation does not last

that long; open committee discussion, 9

a.m. to 5 p.m.; Leander B. Madoo,

Center for Drug Evaluation and Research

(HFD–9), Food and Drug

Administration, 5600 Fishers Lane,

Rockville, MD 20857, 301–443–4695, or
Federal Register / Vol. 60, No. 52 / Friday, March 17, 1995 / Notices 14437

FDA Advisory Committee Information

Hotline, 1–800–741–8138 (301–443–

0572 in the Washington, DC area)

Pulmonary-Allergy Drugs Advisory

Committee, code 12545.

General function of the committee.

The committee reviews and evaluates

data on the safety and effectiveness of

marketed and investigational human

drugs for use in the treatment of

pulmonary disease and diseases with

allergic and/or immunologic

mechanisms.

Agenda—Open public hearing.

Interested persons may present data,

information, or views, orally or in

writing, on issues pending before the

committee. Those desiring to make

formal presentations should notify the

contact person before March 24, 1995,

and submit a brief statement of the

general nature of the evidence or

arguments they wish to present, the

names and addresses of proposed

participants, and an indication of the

approximate time required to make their

comments.

Open committee discussion. The

committee will discuss new drug

application (NDA) 20–471, Abbott

Laboratories, Leutrol (zileuton) as an

anti-asthmatic drug.

Dental Drug Products Panel Plaque

Subcommittee (Nonprescription

Drugs) of the Medical Devices

Advisory Committee

Date, time, and place. April 10, 11,

and 12, 1995, 9 a.m., Parklawn Bldg.,

conference room G, 5600 Fishers Lane,

Rockville, MD.

Type of meeting and contact person.

Open public hearing, April 10, 1995, 9

a.m. to 11 a.m., unless public

participation does not last that long;

open committee discussion, 11 a.m. to

5 p.m.; open public hearing, April 11,

1995, 9 a.m. to 11 a.m., unless public

participation does not last that long;

open committee discussion, 11 a.m. to

5 p.m.; open public hearing, April 12,

1995, 9 a.m. to 11 a.m., unless public

participation does not last that long;

open committee discussion, 11 a.m. to

4 p.m.; Jeanne L. Rippere or Stephanie

A. Mason, Center for Drug Evaluation

and Research (HFD–813), Food and

Drug Administration, 7520 Standish Pl.,

Rockville, MD 20855, 301–594–1003, or

FDA Advisory Committee Information

Hotline, 1–800–741–8138 (301–443–

0572 in the Washington, DC area),

Dental Products Panel of the Medical

Devices Advisory Committee, code

12518.

General function of the committee.

The committee reviews and evaluates

data on the safety and effectiveness of

marketed and investigational devices

and makes recommendations for their

regulation.

The Dental Products Panel of the

Medical Devices Advisory Committee

functions at times as a nonprescription

drug advisory panel. As such, the panel

reviews and evaluates available data

concerning the safety and effectiveness

of active ingredients, and combinations

thereof, of various currently marketed

nonprescription drug products for

human use, the adequacy of their

labeling, and advises the Commissioner

of Food and Drugs on the promulgation

of monographs establishing conditions

under which these drugs are generally

recognized as safe and effective and not

misbranded.

Agenda—Open public hearing.

Interested persons may present data,

information, or views, orally or in

writing, on the general issues pending

before the subcommittee. Those desiring

to make formal presentations should

notify the contact person before April 5,

1995, and submit a brief statement of

the general nature of the evidence or

arguments they wish to present, the

names and addresses of proposed

participants, and an indication of the

approximate time required to make their

comments.

Open committee discussion. The

subcommittee will continue with its

discussion begun during the December

5 and 7, 1994, meeting on developing

general guidelines for determining the

safety and effectiveness of antiplaque

and antiplaque-related drug products.

The subcommittee will also begin

discussion on the safety and

effectiveness of the ingredients stannous

fluoride, zinc citrate, peppermint oil,

and sage oil for antiplaque and

antiplaque-related uses.

Ear, Nose, and Throat Devices Panel

of the Medical Devices Advisory

Committee

Date, time, and place. April 20, 1995,

8 a.m., Corporate Bldg., Main

Conference Room, 9200 Corporate Blvd.,

Rockville, MD. A limited number of

overnight accommodations are available

at the Holiday Inn—Gaithersburg, Two

Montgomery Village Ave., Gaithersburg,

MD. Attendees requiring overnight

accommodations may contact the hotel

at 301–948–8900 and reference the FDA

Panel meeting block. Reservations will

be confirmed at the group rate based on

availability.

Type of meeting and contact person.

Open public hearing, 8 a.m. to 9 a.m.,

unless public participation does not last

that long; open committee discussion, 9

a.m. to 6 p.m.; Harry R. Sauberman,

Center for Devices and Radiological

Health (HFZ–470), Food and Drug

Administration, 9200 Corporate Blvd.,

Rockville, MD 20850, 301–594–2080, or

FDA Advisory Committee Information

Hotline, 1–800–741–8138 (301–443–

0572 in the Washington, DC area), Ear,

Nose, and Throat Devices Panel, code

12522. If anyone who is planning to

attend the meeting will need any special

assistance as defined under the

Americans with Disabilities Act, please

notify the contact person above.

General function of the committee.

The committee reviews and evaluates

data on the safety and effectiveness of

marketed and investigational devices

and makes recommendations for their

regulation.

Agenda—Open public hearing.

Interested persons may present data,

information, or views, orally or in

writing, on issues pending before the

committee. Those desiring to make

formal presentations should notify the

contact person before April 10, 1995,

and submit a brief statement of the

general nature of the evidence or

arguments they wish to present, the

names and addresses of proposed

participants, and an indication of the

approximate time required to make their

comments.

Open committee discussion. The

committee will discuss a supplement to

a premarket approval application that

seeks to expand the indication for use

for an approved cochlear implant device

to include postlinguistically hearingimpaired adults who demonstrate

severe-to-profound hearing loss and

who obtain some minimal benefit from

conventional amplification. The

discussion will include the review of

clinical data obtained with the use of

various speech processors.

National Mammography Quality

Assurance Advisory Committee

Date, time, and place. April 24, 1995,

10 a.m., and April 25 and 26, 1995, 9

a.m., Dupont Plaza Hotel, 1500 New

Hampshire Ave. NW., Washington, DC.

A limited number of overnight

accommodations have been reserved at

the Dupont Plaza Hotel. Attendees

requiring overnight accommodations

may contact the hotel at 202–483–6000

and reference the FDA Committee

meeting block. Reservations will be

confirmed at the group rate based on

availability.

Type of meeting and contact person.

Open committee discussion, April 24,

1995, 10 a.m. to 3 p.m.; open

subcommittee discussions, 3 p.m. to 5

p.m.; open subcommittee discussions,

April 25, 1995, 9 a.m. to 5 p.m.; open
14438 Federal Register / Vol. 60, No. 52 / Friday, March 17, 1995 / Notices

public hearing, April 26, 1995, 9 a.m. to

10 a.m., unless public participation does

not last that long; open committee

discussion, 10 a.m. to 3 p.m.; Charles K.

Showalter, Center for Devices and

Radiological Health (HFZ–240), Food

and Drug Administration, 1350 Piccard

Dr., Rockville, MD 20850, 301–594–

3332, or FDA Advisory Committee

Information Hotline, 1–800–741–8138

(301–443–0572 in the Washington, DC

area), National Mammography Quality

Assurance Advisory Committee, code

12397.

General function of the committee.

The committee advises on developing

appropriate quality standards and

regulations for the use of mammography

facilities.

Agenda—Open public hearing.

Interested persons may present data,

information, or views, orally or in

writing, on issues pending before the

committee. Those desiring to make

formal presentations should notify the

contact person before April 18, 1995,

and submit a brief statement of the

general nature of the evidence or

arguments they wish to present, the

names and addresses of proposed

participants, and an indication of the

approximate time required to make their

comments.

Open committee discussion. On April

24 and 26, 1995, the committee will

discuss: (1) The development of three

working groups (i.e., subcommittees) to

consider access to mammography

services, physicists availability, and cost

benefit of compliance; (2) the

Congressional reports and

determinations mandated in the

Mammography Quality Standards Act

(the MQSA); (3) the work of the

subcommittees; and (4) a briefing on

inspections to date.

Open subcommittee discussions. On

April 24 and 25, 1995, the three

subcommittees will meet concurrently.

The subcommittees will discuss

preliminary information which is

necessary to make the determinations

and subsequently prepare the reports as

mandated in the MQSA. Upon

completion, the subcommittee reports

will be reviewed by the committee prior

to submission to the Secretary and

Congress.

Subcommittees of the National Task

Force on AIDS Drug Development

Date, time, and place. April 25, 1995,

8:30 a.m.; April 26, 1995, 10 a.m.;

Salons 1, 2, and 3, Congressional

Ballroom; Bethesda Marriott, 5151

Pooks Hill Rd., Bethesda, MD.

Type of meeting and contact person.

Open subcommittee discussion, April

25, 1995, 8:30 a.m. to 4:30 p.m.; open

public hearing, 4:30 p.m. to 5:30 p.m.,

unless public participation does not last

that long; open subcommittee

discussions, April 26, 1995, 10 a.m. to

4:30 p.m.; open public hearing, 4:30

p.m. to 5:30 p.m., unless public

participation does not last that long;

Jean H. McKay or Kimberley M. Miles,

Office of AIDS and Special Health

Issues (HF–12), Food and Drug

Administration, 5600 Fishers Lane,

Rockville, MD 20857, 301–443–0104, or

FDA Advisory Committee Information

Hotline, 1–800–741–8138 (301–443–

0572 in the Washington, DC area),

National Task Force on AIDS Drug

Development, code 12602.

General function of the task force. The

National Task Force on AIDS Drug

Development shall identify any barriers

and provide creative options for the

rapid development and evaluation of

treatments for human

immunodeficiency virus (HIV) infection

and its sequelae. It also advises on

issues related to such barriers, and

provides options for the elimination of

these barriers.

Open task force discussion. The four

subcommittees of the task force will

meet to discuss barriers related to the

identification of specific drug targets

and solutions to these barriers in

preparation for the next full meeting of

the task force. Members of the

subcommittees, Federal government,

and the public will participate in these

discussions.

Agenda—Open public hearing.

Interested persons may present data,

information, or views, orally or in

writing, on issues pending before the

task force. Those desiring to make

formal presentations should notify the

contact person before April 19, 1995,

and submit a brief statement of the

general nature of the evidence or

arguments they wish to present, the

names and addresses of proposed

participants, and an indication of the

approximate time required to make their

comments.

FDA public advisory committee

meetings may have as many as four

separable portions: (1) An open public

hearing, (2) an open committee

discussion, (3) a closed presentation of

data, and (4) a closed committee

deliberation. Every advisory committee

meeting shall have an open public

hearing portion. Whether or not it also

includes any of the other three portions

will depend upon the specific meeting

involved. There are no closed portions

for the meetings announced in this

notice. The dates and times reserved for

the open portions of each committee

meeting are listed above.

The open public hearing portion of

each meeting shall be at least 1 hour

long unless public participation does

not last that long. It is emphasized,

however, that the 1 hour time limit for

an open public hearing represents a

minimum rather than a maximum time

for public participation, and an open

public hearing may last for whatever

longer period the committee

chairperson determines will facilitate

the committee’s work.

Public hearings are subject to FDA’s

guideline (subpart C of 21 CFR part 10)

concerning the policy and procedures

for electronic media coverage of FDA’s

public administrative proceedings,

including hearings before public

advisory committees under 21 CFR part

14. Under 21 CFR 10.205,

representatives of the electronic media

may be permitted, subject to certain

limitations, to videotape, film, or

otherwise record FDA’s public

administrative proceedings, including

presentations by participants.

Meetings of advisory committees shall

be conducted, insofar as is practical, in

accordance with the agenda published

in this Federal Register notice. Changes

in the agenda will be announced at the

beginning of the open portion of a

meeting.

Any interested person who wishes to

be assured of the right to make an oral

presentation at the open public hearing

portion of a meeting shall inform the

contact person listed above, either orally

or in writing, prior to the meeting. Any

person attending the hearing who does

not in advance of the meeting request an

opportunity to speak will be allowed to

make an oral presentation at the

hearing’s conclusion, if time permits, at

the chairperson’s discretion.

The agenda, the questions to be

addressed by the committee, and a

current list of committee members will

be available at the meeting location on

the day of the meeting.

Transcripts of the open portion of the

meeting may be requested in writing

from the Freedom of Information Office

(HFI–35), Food and Drug

Administration, rm. 12A–16, 5600

Fishers Lane, Rockville, MD 20857,

approximately 15 working days after the

meeting, at a cost of 10 cents per page.

The transcript may be viewed at the

Dockets Management Branch (HFA–

305), Food and Drug Administration,

rm. 1–23, 12420 Parklawn Dr.,

Rockville, MD 20857, approximately 15

working days after the meeting, between

the hours of 9 a.m. and 4 p.m., Monday

through Friday. Summary minutes of

the open portion of the meeting may be

requested in writing from the Freedom

of Information Office (address above)
Federal Register / Vol. 60, No. 52 / Friday, March 17, 1995 / Notices 14439

beginning approximately 90 days after

the meeting.

This notice is issued under section

10(a)(1) and (2) of the Federal Advisory

Committee Act (5 U.S.C. app. 2), and

FDA’s regulations (21 CFR part 14) on

advisory committees.

Dated: March 13, 1995.

Lireka P. Joseph,

Acting Deputy Commissioner for Operations.

[FR Doc. 95–6692 Filed 3–16–95; 8:45 am]

BILLING CODE 4160–01–F

National Institutes of Health

National Cancer Institute; Notice of

Meetings

Pursuant to Pub. L. 92–463, notice is

hereby given of the meetings of the

National Cancer Institute for April and

May 1995.

These meetings will be open to the

public to discuss administrative details

or other issues relating to committee

activities as indicated in the notice and

for the review of concepts being

considered for funding. Attendance by

the public will be limited to space

available.

These meetings will be closed to the

public as indicated below in accordance

with the provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

and sec. 10(d) of Pub. L. 92–463, for the

review, discussion and evaluation of

individual grant applications and

contract proposals. These applications

and proposals and the discussions could

reveal confidential trade secrets or

commercial property such as patentable

material, and personal information

concerning individuals associated with

the applications and proposals, the

disclosure of which would constitute a

clearly unwarranted invasion of

personal privacy.

Ms. Carole Frank, the Committee

Management Officer, National Cancer

Institute, Executive Plaza North, Room

630E, 6130 Executive Blvd MSC 7405,

Bethesda, Maryland 20892–7405, (301–

496–5708) will provide a summary of

the meetings and the roster of

committee members, upon request.

Other information pertaining to the

meetings may be obtained from the

contact person indicated below.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodation, should

contact the Executive Secretary/

Scientific Review Administrator listed

for that particular meeting.

Committee name: Cancer Centers and

Research Programs Review Committee—

Subcommittee D.

Contact person: Dr. John W. Abrell,

Scientific Review Administrator, National

Cancer Institute, Bldg. EPN, Room 635B,

6130 Executive Blvd MSC 7405, Bethesda,

MD 20892–7405, Telephone: (301) 496–9767.

Date of meeting: April 11–12, 1995.

Place of meeting: The Holiday Inn Crowne

Plaza, 1750 Rockville Pike, Rockville, MD

20852.

Closed: 8 am to adjournment.

Agenda: Review, discussion and

evaluation of individual grant applications.

Committee name: Biometry and

Epidemiology Contract Review Committee.

Contact person: Dr. Harvey P. Stein,

Scientific Review Administrator, National

Cancer Institute, Bldg. EPN, Room 601C,

6130 Executive Blvd MSC 7405, Bethesda,

MD 20892–7405, Telephone: (301) 496–7030.

Date of meeting: April 12–13, 1995.

Place of meeting: Conference Room G, 6130

Executive Blvd., Rockville, MD 20852.

Closed: 9 am to adjournment.

Agenda: Review, discussion and

evaluation of individual contract proposals.

Committee name: Acrylonitrile Study

Advisory Panel.

Contact person: Dr. Aaron Blair, Executive

Secretary, National Cancer Institute, 6130

Executive Blvd., Room 418, Rockville, MD

20852, Telephone: (301) 496–9093.

Date of meeting: May 3, 1995.

Place of meeting: Conference Rooms 1 & 2,

6100 Executive Blvd., Rockville, MD 20852.

Open: 10 am to adjournment.

Agenda: Review and discussion of study

progress.

(Catalog of Federal Domestic Assistance

Program Numbers: 93.393, Cancer Cause and

Prevention Research; 93.394, Cancer

Detection and Diagnosis Research; 93.395,

Cancer Treatment Research; 93.396, Cancer

Biology Research; 93.397, Cancer Centers

Support; 93.398, Cancer Research Manpower;

93.399, Cancer Control.)

Dated: March 13, 1995.

Margery G. Grubb,

Senior Committee Management Specialist,

NIH.

[FR Doc. 95–6570 Filed 3–16–95; 8:45 am]

BILLING CODE 4140–01–M

National Institute on Deafness and

Other Communication Disorders;

Notice of Meeting of the Ad Hoc

Hearing and Hearing Impairment

Subcommittee of the National

Deafness and Other Communication

Disorders Advisory Council

Pursuant to Pub. L. 92–463, notice is

hereby given of the meeting of the Ad

Hoc Hearing and Hearing Impairment

Subcommittee of the National Deafness

and Other Communication Disorders

Advisory Council on April 6, 1995. The

meeting will take place from 1 p.m. to

4 p.m. in Conference Room 9, Building

31C, National Institutes of Health, 9000

Rockville Pike, Bethesda, Maryland

20892, and will be conducted as a

telephone conference with the use of a

speaker phone.

The meeting, which is open to the

public, will be held to discuss changes

in the scientific field of hearing and

hearing impairment since the Research

Plan was written, compare the research

portfolio of the Institute with the

priorities in the Research Plan to

determine areas of emphasis and levels

of activity, and to identify gaps and to

suggest new initiatives in preparation

for the updating of the hearing and

hearing impairment section of the

Research Plan. Attendance by the public

will be limited to the space available.

Summaries of the Subcommittee’s

meeting and a roster of members may be

obtained from Mr. Baldwin Wong,

Program Analyst, National Institute on

Deafness and Other Communication

Disorders, Building 31, Room 3C08,

National Institutes of Health, Bethesda,

Maryland 20892, (301) 402–1129, upon

request.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

contact Mr. Wong in advance of the

meeting.

(Catalog of Federal Domestic Assistance

Program No. 93.173, Biological Research

Related to Deafness and Communication

Disorders)

Dated: March 13, 1995.

Margery G. Grubb,

Senior Committee Management Specialist,

NIH.

[FR Doc. 95–6569 Filed 3–16–95; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Dental Research;

Notice of Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

National Institute of Dental Research

Special Emphasis Panel (SEP) meetings.

Name of SEP: National Institute of Dental

Research Special Emphasis Panel-Perio.

Complications of Diabetes.

Dates: April 13, 1995.

Time: 9:00 a.m.

Place: Natcher Building, NIH, Conf. Center

A.

Contact Person: Dr. Yong Shin, Scientist

Review Administrator, 4500 Center Drive,

Natcher Building, Room 4AN–38J, Bethesda,

MD 20892, (301) 594–2372.

Purpose/Agenda: To evaluate and review

grant applications and/or contract proposals.

Name of SEP: National Institute of Dental

Research Special Emphasis Panel-Sensor for

High Resolution (Teleconference).

Dates: April 17, 1995.